AMN
AMN Healthcare Services, Inc.
Medical - Care Facilities
Market Cap$811M
5Y Perf.-52.7%
Compare Stocks
3 / 10Try these comparisons:
Stock Comparison
AMN vs CHE vs CCRN
Revenue, margins, valuation, and 5-year total return — side by side.
CHE
Chemed Corporation
Medical - Care Facilities
Market Cap$5.81B
5Y Perf.-11.3%
CCRN
Cross Country Healthcare, Inc.
Medical - Care Facilities
Market Cap$326M
5Y Perf.+66.6%
AMN vs CHE vs CCRN — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | AMN | CHE | CCRN |
|---|---|---|---|
| Industry | Medical - Care Facilities | Medical - Care Facilities | Medical - Care Facilities |
| Market Cap | $811M | $5.81B | $326M |
| Revenue (TTM) | $2.73B | $2.54B | $1.05B |
| Net Income (TTM) | $-96M | $260M | $-95M |
| Gross Margin | 25.7% | 22.5% | 18.7% |
| Operating Margin | -3.5% | 12.9% | -0.3% |
| Forward P/E | 10.3x | 17.4x | 103.4x |
| Total Debt | $803M | $155M | $2M |
| Cash & Equiv. | $34M | $75M | $109M |
AMN vs CHE vs CCRN — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
AMN
CHE
CCRN
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| AMN Healthcare Serv… (AMN) | 100 | 47.3 | -52.7% |
| Chemed Corporation (CHE) | 100 | 88.7 | -11.3% |
| Cross Country Healt… (CCRN) | 100 | 166.6 | +66.6% |
Price return only. Dividends and distributions are not included.
Quick Verdict: AMN vs CHE vs CCRN
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: CHE leads in 5 of 7 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. AMN Healthcare Services, Inc. is the stronger pick specifically for valuation and capital efficiency and recent price momentum and sentiment. As sector peers, any of these can serve as alternatives in the same allocation.
AMN
AMN Healthcare Services, Inc.
The Value Play
AMN is the clearest fit if your priority is value and momentum.
- Lower P/E (10.3x vs 103.4x)
- +7.1% vs CCRN's -26.6%
Best for: value and momentum
CHE
Chemed Corporation
The Income Pick
CHE carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- Dividend streak 18 yrs, beta 0.33, yield 0.5%
- Rev growth 4.1%, EPS growth -7.4%, 3Y rev CAGR 5.8%
- 239.1% 10Y total return vs CCRN's -28.1%
Best for: income & stability and growth exposure
CCRN
Cross Country Healthcare, Inc.
The Secondary Option
CCRN plays a supporting role in this comparison — it may shine differently against other peers.
Best for: healthcare exposure
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | CHE | 4.1% revenue growth vs CCRN's -21.6% |
| Value | AMN | Lower P/E (10.3x vs 103.4x) |
| Quality / Margins | CHE | 10.2% margin vs CCRN's -9.0% |
| Stability / Safety | CHE | Beta 0.33 vs AMN's 1.08, lower leverage |
| Dividends | CHE | 0.5% yield; 18-year raise streak; the other 2 pay no meaningful dividend |
| Momentum (1Y) | AMN | +7.1% vs CCRN's -26.6% |
| Efficiency (ROA) | CHE | 15.9% ROA vs CCRN's -17.9%, ROIC 23.7% vs -0.9% |
AMN vs CHE vs CCRN — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2025
FY 2025
FY 2024
AMN vs CHE vs CCRN — Financial Metrics
Side-by-side numbers across 3 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLCHELAGGINGCCRN
CCRNCross Country Healthc…
0leads
AMNAMN Healthcare Servic…
1leads
CHEChemed Corporation
3leads
6 Total Categories
CATEGORYLEADERvs AMNvs CCRNMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
Tied
—
Valuation MetricsMultiples, price ratios, and targets
AMN5/6
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
CHE5/9
Total Returns1Y, 3Y, 5Y total returns with dividends
CHE4/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
CHE1/1
Income & Cash Flow (Last 12 Months)
Evenly matched — AMN and CHE each lead in 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
AMN is the larger business by revenue, generating $2.7B annually — 2.6x CCRN's $1.1B. CHE is the more profitable business, keeping 10.2% of every revenue dollar as net income compared to CCRN's -9.0%. On growth, AMN holds the edge at +1.8% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | AMNAMN Healthcare Se… | CHEChemed Corporation | CCRNCross Country Hea… |
|---|---|---|---|
| RevenueTrailing 12 months | $2.7B | $2.5B | $1.1B |
| EBITDAEarnings before interest/tax | $62M | $377M | $13M |
| Net IncomeAfter-tax profit | -$96M | $260M | -$95M |
| Free Cash FlowCash after capex | $234M | $377M | $42M |
| Gross MarginGross profit ÷ Revenue | +25.7% | +22.5% | +18.7% |
| Operating MarginEBIT ÷ Revenue | -3.5% | +12.9% | -0.3% |
| Net MarginNet income ÷ Revenue | -3.5% | +10.2% | -9.0% |
| FCF MarginFCF ÷ Revenue | +8.6% | +14.8% | +4.0% |
| Rev. Growth (YoY)Latest quarter vs prior year | +1.8% | +1.6% | -23.6% |
| EPS Growth (YoY)Latest quarter vs prior year | +95.9% | -0.2% | -20.3% |
Evenly matched — AMN and CHE each lead in 3 of 6 comparable metrics.
Valuation Metrics
AMN leads this category, winning 5 of 6 comparable metrics.
Valuation Metrics
On an enterprise value basis, AMN's 8.3x EV/EBITDA is more attractive than CCRN's 16.5x.
| Metric | AMNAMN Healthcare Se… | CHEChemed Corporation | CCRNCross Country Hea… |
|---|---|---|---|
| Market CapShares × price | $811M | $5.8B | $326M |
| Enterprise ValueMkt cap + debt − cash | $1.6B | $5.9B | $220M |
| Trailing P/EPrice ÷ TTM EPS | -8.46x | 23.05x | -3.45x |
| Forward P/EPrice ÷ next-FY EPS est. | 10.31x | 17.43x | 103.37x |
| PEG RatioP/E ÷ EPS growth rate | — | — | — |
| EV / EBITDAEnterprise value multiple | 8.33x | 14.60x | 16.49x |
| Price / SalesMarket cap ÷ Revenue | 0.30x | 2.29x | 0.31x |
| Price / BookPrice ÷ Book value/share | 1.26x | 6.24x | 1.01x |
| Price / FCFMarket cap ÷ FCF | 3.47x | 17.84x | 6.76x |
AMN leads this category, winning 5 of 6 comparable metrics.
Profitability & Efficiency
CHE leads this category, winning 5 of 9 comparable metrics.
Profitability & Efficiency
CHE delivers a 25.3% return on equity — every $100 of shareholder capital generates $25 in annual profit, vs $-24 for CCRN. CCRN carries lower financial leverage with a 0.01x debt-to-equity ratio, signaling a more conservative balance sheet compared to AMN's 1.25x. On the Piotroski fundamental quality scale (0–9), CCRN scores 6/9 vs CHE's 5/9, reflecting solid financial health.
| Metric | AMNAMN Healthcare Se… | CHEChemed Corporation | CCRNCross Country Hea… |
|---|---|---|---|
| ROE (TTM)Return on equity | -14.7% | +25.3% | -24.3% |
| ROA (TTM)Return on assets | -4.3% | +15.9% | -17.9% |
| ROICReturn on invested capital | +1.6% | +23.7% | -0.9% |
| ROCEReturn on capital employed | +2.0% | +24.7% | -0.8% |
| Piotroski ScoreFundamental quality 0–9 | 5 | 5 | 6 |
| Debt / EquityFinancial leverage | 1.25x | 0.16x | 0.01x |
| Net DebtTotal debt minus cash | $769M | $80M | -$106M |
| Cash & Equiv.Liquid assets | $34M | $75M | $109M |
| Total DebtShort + long-term debt | $803M | $155M | $2M |
| Interest CoverageEBIT ÷ Interest expense | -1.22x | 107.24x | -1.56x |
CHE leads this category, winning 5 of 9 comparable metrics.
Total Returns (Dividends Reinvested)
CHE leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in CHE five years ago would be worth $8,964 today (with dividends reinvested), compared to $2,366 for AMN. Over the past 12 months, AMN leads with a +7.1% total return vs CCRN's -26.6%. The 3-year compound annual growth rate (CAGR) favors CHE at -8.0% vs AMN's -38.5% — a key indicator of consistent wealth creation.
| Metric | AMNAMN Healthcare Se… | CHEChemed Corporation | CCRNCross Country Hea… |
|---|---|---|---|
| YTD ReturnYear-to-date | +38.7% | +0.3% | +25.4% |
| 1-Year ReturnPast 12 months | +7.1% | -26.0% | -26.6% |
| 3-Year ReturnCumulative with dividends | -76.8% | -22.1% | -57.0% |
| 5-Year ReturnCumulative with dividends | -76.3% | -10.4% | -37.2% |
| 10-Year ReturnCumulative with dividends | -44.1% | +239.1% | -28.1% |
| CAGR (3Y)Annualised 3-year return | -38.5% | -8.0% | -24.5% |
CHE leads this category, winning 4 of 6 comparable metrics.
Risk & Volatility
Evenly matched — AMN and CHE each lead in 1 of 2 comparable metrics.
Risk & Volatility
CHE is the less volatile stock with a 0.33 beta — it tends to amplify market swings less than AMN's 1.08 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. AMN currently trades 88.4% from its 52-week high vs CCRN's 67.4% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | AMNAMN Healthcare Se… | CHEChemed Corporation | CCRNCross Country Hea… |
|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.08x | 0.33x | 0.78x |
| 52-Week HighHighest price in past year | $23.74 | $583.96 | $14.99 |
| 52-Week LowLowest price in past year | $14.87 | $365.20 | $7.43 |
| % of 52W HighCurrent price vs 52-week peak | +88.4% | +72.7% | +67.4% |
| RSI (14)Momentum oscillator 0–100 | 60.3 | 67.6 | 67.4 |
| Avg Volume (50D)Average daily shares traded | 839K | 275K | 451K |
Evenly matched — AMN and CHE each lead in 1 of 2 comparable metrics.
Analyst Outlook
CHE leads this category, winning 1 of 1 comparable metric.
Analyst Outlook
Analyst consensus: AMN as "Buy", CHE as "Hold", CCRN as "Hold". Consensus price targets imply 11.9% upside for CHE (target: $475) vs 4.9% for CCRN (target: $11). CHE is the only dividend payer here at 0.52% yield — a key consideration for income-focused portfolios.
| Metric | AMNAMN Healthcare Se… | CHEChemed Corporation | CCRNCross Country Hea… |
|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Hold | Hold |
| Price TargetConsensus 12-month target | $22.50 | $475.00 | $10.61 |
| # AnalystsCovering analysts | 17 | 9 | 14 |
| Dividend YieldAnnual dividend ÷ price | — | +0.5% | — |
| Dividend StreakConsecutive years of raises | — | 18 | 1 |
| Dividend / ShareAnnual DPS | — | $2.20 | — |
| Buyback YieldShare repurchases ÷ mkt cap | +0.3% | +7.4% | 0.0% |
CHE leads this category, winning 1 of 1 comparable metric.
Key Takeaway
CHE leads in 3 of 6 categories (Profitability & Efficiency, Total Returns). AMN leads in 1 (Valuation Metrics). 2 tied.
Best OverallChemed Corporation (CHE)Leads 3 of 6 categories
Loading custom metrics...
AMN vs CHE vs CCRN: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is AMN or CHE or CCRN a better buy right now?
For growth investors, Chemed Corporation (CHE) is the stronger pick with 4.
1% revenue growth year-over-year, versus -21. 6% for Cross Country Healthcare, Inc. (CCRN). Chemed Corporation (CHE) offers the better valuation at 23. 0x trailing P/E (17. 4x forward), making it the more compelling value choice. Analysts rate AMN Healthcare Services, Inc. (AMN) a "Buy" — based on 17 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — AMN or CHE or CCRN?
On forward P/E, AMN Healthcare Services, Inc.
is actually cheaper at 10. 3x — notably different from the trailing picture, reflecting expected earnings growth.
03Which is the better long-term investment — AMN or CHE or CCRN?
Over the past 5 years, Chemed Corporation (CHE) delivered a total return of -10.
4%, compared to -76. 3% for AMN Healthcare Services, Inc. (AMN). Over 10 years, the gap is even starker: CHE returned +239. 1% versus AMN's -44. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — AMN or CHE or CCRN?
By beta (market sensitivity over 5 years), Chemed Corporation (CHE) is the lower-risk stock at 0.
33β versus AMN Healthcare Services, Inc. 's 1. 08β — meaning AMN is approximately 231% more volatile than CHE relative to the S&P 500. On balance sheet safety, Cross Country Healthcare, Inc. (CCRN) carries a lower debt/equity ratio of 1% versus 125% for AMN Healthcare Services, Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — AMN or CHE or CCRN?
By revenue growth (latest reported year), Chemed Corporation (CHE) is pulling ahead at 4.
1% versus -21. 6% for Cross Country Healthcare, Inc. (CCRN). On earnings-per-share growth, the picture is similar: AMN Healthcare Services, Inc. grew EPS 35. 6% year-over-year, compared to -565. 9% for Cross Country Healthcare, Inc.. Over a 3-year CAGR, CHE leads at 5. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — AMN or CHE or CCRN?
Chemed Corporation (CHE) is the more profitable company, earning 10.
5% net margin versus -9. 0% for Cross Country Healthcare, Inc. — meaning it keeps 10. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CHE leads at 13. 4% versus -0. 3% for CCRN. At the gross margin level — before operating expenses — CHE leads at 30. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is AMN or CHE or CCRN more undervalued right now?
On forward earnings alone, AMN Healthcare Services, Inc.
(AMN) trades at 10. 3x forward P/E versus 103. 4x for Cross Country Healthcare, Inc. — 93. 1x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for CHE: 11. 9% to $475. 00.
08Which pays a better dividend — AMN or CHE or CCRN?
In this comparison, CHE (0.
5% yield) pays a dividend. AMN, CCRN do not pay a meaningful dividend and should not be held primarily for income.
09Is AMN or CHE or CCRN better for a retirement portfolio?
For long-horizon retirement investors, Chemed Corporation (CHE) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
33), 0. 5% yield, +239. 1% 10Y return). Both have compounded well over 10 years (CHE: +239. 1%, AMN: -44. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between AMN and CHE and CCRN?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
CHE pays a dividend while AMN, CCRN do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
Revenue Growth>
%
(AMN: 1.8% · CHE: 1.6%)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.